consider ahead quarterli result
highlight sever key topic upcom catalyst ahead quarterli fy
result hcv script data suggest mavyret market share
guidanc hcv sale drive quarterli royalti estim
vs consensu estimate rsv rsvp adult outpati
data expect studi adult pediatr transplant patient
initi nash trial initi earli
pbc intrepid data expect follow-on fxr-agonist
nash studi initi core-inhibitor hbv data
healthi volunt expect updat model script lower
pt detail insid
estim quarterli hcv royalti vs consensu estimate
base updat script data suggest mavyret market share
guidanc total hcv sale guid
sg estim quarterli ep vs
consensu pipelin fulli fund hcv royalti exhibit
rsv rsvp adult outpati studi on-going data expect
approach describ fda draft guidanc develop antivir
rsv treatment prophylaxi suspect support studi
target popul need secur adopt hcps/payer addit
studi adult pediatr transplant patient initi exhibit
trial biopsy-proven nash plan
initi earli design similar flint primari endpoint fibrosi
studi includ interim analysi may simultan explor
combin seek partner develop pbc intrepid data
expect exhibit
follow-on fxr-agonist studi expect initi
top-line data expect may improv liver gi-direct
distribut increas potenc potenti allow lower dose
reduc pruritu vs fxr note ldl-c increas like
core-inhibitor hbv sad mad pk data
healthi volunt expect evalu antivir efficaci nuc-
suppress chronic-hbv patient start addit studi
viremic-hbv patient initi sotp analysi valu hcv royalti
nash rsv lower pt
exhibit
year price histori
chemistry-driven approach drug
discoveri capabl creat small
molecul drug viral infect
hepat viru
respiratori syncyti viru rsv
analyst certif import disclosur see disclosur
assum hcv royalti fund on-going develop
pipelin asset potenti bd
assum hcv stabl
assum develop nash rsv
acceler enter market
estim pbc nash respect
greater expect sale mavyret
hbv rsv drug acceler clinic progress
enta uniqu approach drug develop focus
thorough optim compound could provid competit
advantag nash pbc compani success
demonstr hcv mavyret expect continu
perform mavyret hcv deliv royalti fund
develop new pipelin asset nash pbc hbv
hbv part sad mad data
nash trial initi
pbc intrepid data
rsv rsvp data
fail develop nash pbc
mavyret fail defend market share
price target base dcf valuat methodolog assum wacc residu growth rate
due patent expir model
key downsid risk clinic develop risk regulatori risk current phase trial addit risk come
lower expect peak sale market hcv drug due higher anticip competit failur
gain support medic commun healthcar prescrib third-parti payor
exhibit estim quarterli hcv royalti vs consensu base
updat script data suggest mavyret current market share total hcv sale
guidanc estim cash balanc
exhibit enta pipelin fulli fund hcv royalti
exhibit rsv rsvp adult outpati studi on-going data expect
approach describ fda draft guidanc develop antivir rsv treatment
prophylaxi support studi target popul need secur adopt
exhibit trial biopsy-proven nash plan initi
primari endpoint fibrosi improv without nash worsen and/or vice-versa
across two dose group studi includ interim analysi
exhibit follow-on fxr-agonist studi initi top-line data
may improv liver gi-direct distribut may increas potenc
potenti allow lower dose reduc pruritu vs fxr
exhibit core-inhibitor sad mad pk data healthi volunt
expect start evalu antivir efficaci nuc-suppress chronic hbv
patient addit studi virem hbv patient initi
exhibit hypothet sotp analysi valu hcv royalti nash
rsv
exhibit lower pt base dcf valuat
drug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successp-adj npv mm sotp p-adj valu shareroyalti equiti share outstand use valuat oppenheim co enanta discount analysi except per share data fy revenu growth chang work work capit valu growth valu oppenheim co equiti valu per sharetermin valu growth rate perform
nash
probabl success
risk-adjust nash
rsv
probabl success
risk-adjust rsv
collabor revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex
interest dividend incom
stock price compani mention report jan
